Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024582 | 1.00 | DPP4 (0.54) | DPP4RETMAP4K4SUV39H2SYK | |
| SCHEMBL2020037 | 0.91 | DPP4 (0.54) | DPP4RETMAP4K4KDM4DDDR1 | |
| SCHEMBL2020035 | 0.91 | DPP4 (0.54) | DPP4RETMAP4K4KDM4DDDR1 | |
| SCHEMBL2200504 | 0.90 | DPP4 (0.57) | DPP4 | |
| SCHEMBL2022446 | 0.89 | DPP4 (0.69) | DPP4RET | |
| SCHEMBL2022448 | 0.89 | DPP4 (0.69) | DPP4RET | |
| SCHEMBL2020192 | 0.81 | DPP4 (0.54) | DPP4 | |
| SCHEMBL2020194 | 0.81 | DPP4 (0.54) | DPP4 | |
| SCHEMBL2023360 | 0.80 | DPP4 (0.77) | DPP4 | |
| SCHEMBL18851701 | 0.80 | DPP4 (0.68) | DPP4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | disclosed |
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| WO-2011079778-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | DPP4 1/4885RET 3362/4885MAP4K4 3907/4885 |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | DPP4 1/4885RET 3362/4885MAP4K4 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.